 CAMBRIDGE, Mass. SALISBURY, England--BUSINESS WIRE--- KALV--KalVista Pharmaceuticals, Inc. NASDAQ: KALV, a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that the U.S. Food and Drug Administration FDA has lifted the clinical hold on the Companys Phase 2 clinical trial of KVD824 for oral prophylactic treatment of hereditary angioedema HAE. The execution of KOMPLETE, our Phase 2 clinical 